Novel hemagglutinin-binding sulfated oligofucosides and their effect on influenza virus infection

Kosono, Shuhei; Kasai, Akihiro; Komaba, Sumika; Matsubara, Takahiro; Sato, Toshinori; Takahashi, Daisuke; Toshima, Kazunobu

doi:10.1039/c8cc03865a

Cited by 12 publications

(11 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Toshimaa and co-workers 116 have chemically synthesized a series of fucoidan derivatives to bind HAs of influenza virus and inhibit the hemagglutination activity. Moreover, a synthesized ligand with three sulfated oligofucoside moieties showed attractive hemagglutination inhibition activity.…”

Section: Neuraminidase Inhibitors (Nais)mentioning

confidence: 99%

Recent progress in chemical approaches for the development of novel neuraminidase inhibitors

et al. 2021

View full text Add to dashboard Cite

show abstract

Section: Neuraminidase Inhibitors (Nais)mentioning

confidence: 99%

Recent progress in chemical approaches for the development of novel neuraminidase inhibitors

et al. 2021

View full text Add to dashboard Cite

show abstract

“…[ 242 ] Fucoidans can bind to the virus HA receptor and inhibit virus entry. [ 93 ] The antiviral activity of fucoidans and sulfated fucans have been observed in vitro against HIV, [ 90 ] HSV, [ 89,252 ] and DENV. [ 91 ] Glucans are formed by d ‐glucose monosaccharides and extracted from algae, plants, and fungi.…”

Section: Polymers Against Virusesmentioning

confidence: 99%

From Bulk to Nanoparticles: An Overview of Antiviral Materials, Its Mechanisms, and Applications

Rodrigues

Campo

Arns

et al. 2021

Part & Part Syst Charact

View full text Add to dashboard Cite

Infectious diseases caused by viruses are a global health concern and have become prominent in light of the recent COVID‐19 pandemic. Considering the limitations of drugs and prophylactic methods used in current medicine, antiviral materials are a useful strategy in preventing the spread of viruses and enhancing treatment efficiency. Thus, this review highlights the state‐of‐the‐art antiviral materials, describes the scientific landscape of the primary antiviral materials used based on bibliometric analysis, presents their mechanisms of action, and discusses their clinical applications. The mechanisms of action underlying the broad‐spectrum antiviral properties of metals, ceramics, polymers, and composites are also discussed. Polyanions, polycations, oxides, and metal‐based materials, from bulk to nanoparticles, have good potential in antiviral applications that may help prepare the world for future viral breakouts.

show abstract

“…An interesting new development showed that fucoidan has the ability to prevent gastric mucosa adhesion of the highly infectious norovirus, for which there are no effective preventatives or treatments [14]. Building on earlier research demonstrating the inhibition of influenza viruses by fucoidan, a synthetic fucoidan was shown to be highly effective in binding viral hemagglutinin [71].…”

Section: Microbiome and Fucoidanmentioning

confidence: 99%

Therapies from Fucoidan: New Developments

Fitton¹,

Stringer²,

Park³

et al. 2019

Marine Drugs

136

View full text Add to dashboard Cite

Since our last review in 2015, the study and use of fucoidan has extended in several research areas. Clinical use of fucoidan for the treatment of renal disease has become available and human safety studies have been undertaken on radiolabeled fucoidan for the purpose of imaging thrombi. Fucoidan has been incorporated into an increasing number of commercially available supplements and topical treatments. In addition, new measuring techniques are now available to assess the biologically relevant uptake of fucoidans and to assist in production. Microbiome modulation and anti-pathogenic effects are increasingly promising applications for fucoidans, due to the need for alternative approaches to antibiotic use in the food chain. This review outlines promising new developments in fucoidan research, including potential future therapeutic use.

show abstract

Novel hemagglutinin-binding sulfated oligofucosides and their effect on influenza virus infection

Cited by 12 publications

References 33 publications

Recent progress in chemical approaches for the development of novel neuraminidase inhibitors

Recent progress in chemical approaches for the development of novel neuraminidase inhibitors

From Bulk to Nanoparticles: An Overview of Antiviral Materials, Its Mechanisms, and Applications

Therapies from Fucoidan: New Developments

Contact Info

Product

Resources

About